Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Impella RP Flex with SmartAssist (Photo: Business Wire)
The Impella RP platform includes the world’s smallest percutaneous right heart mechanical circulatory support (MCS) technologies designed to help patients achieve native heart recovery. They do not require extracorporeal blood circulation and remain the only MCS technologies with FDA PMA indications for the treatment of right heart failure.
Key clinical benefits of Impella RP Flex include:
- Single venous access via the internal jugular (IJ) vein and 11 French (Fr) indwelling catheter, facilitating patient mobility
- Flexible cannula advanced over an extra-support guidewire, enabling ease of insertion and pump delivery
- SmartAssist dual-sensor technology with Impella Connect, providing advanced metrics to help with pump management and weaning
- Heparin-free purge, simplifying patient anticoagulant management with the use of sodium bicarbonate where heparin is of concern due to heparin intolerance or bleeding
“Impella RP Flex demonstrates Abiomed’s ongoing commitment to improving patient survival and achieving native heart recovery,” said
Early identification of right heart failure or right ventricular dysfunction and early use of Impella RP is associated with significantly higher survival rates. Studies published in the
“The complexity of right ventricular failure has resulted in patients being underdiagnosed and undertreated,” said
The FDA indication for use of Impella RP Flex with SmartAssist is as follows:
The Impella RP Flex with SmartAssist System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area ≥1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
Impella RP Flex will be introduced in the
ABOUT IMPELLA RP WITH SMARTASSIST
Impella RP® with SmartAssist is
ABOUT
Based in
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005234/en/
Media:
Associate Director,
+1 (978) 882-8491
jleary@abiomed.com
Investor:
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
Source: